BioVie Inc. (NASDAQ:BIVI) Sees Large Increase in Short Interest

BioVie Inc. (NASDAQ:BIVI) was the target of a large increase in short interest in the month of December. As of December 15th, there was short interest totalling 2,090,000 shares, an increase of 13.6% from the November 30th total of 1,840,000 shares. Based on an average daily trading volume, of 5,990,000 shares, the days-to-cover ratio is currently 0.3 days.

BioVie Stock Down 4.3 %

BIVI stock traded down $0.09 during midday trading on Tuesday, reaching $2.00. 1,194,668 shares of the company’s stock traded hands, compared to its average volume of 1,662,104. The firm’s fifty day moving average price is $2.75 and its 200-day moving average price is $1.94. BioVie has a 52 week low of $1.04 and a 52 week high of $33.10. The company has a market cap of $35.54 million, a price-to-earnings ratio of -0.17 and a beta of 0.40.

BioVie (NASDAQ:BIVI) last posted its earnings results on Monday, September 30th. The company reported ($6.60) EPS for the quarter.

BioVie Company Profile

BioVie Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease.